by Bouazza N, Foissac F, Fauchet F, Burger D, Kiechel JR, Treluyer JM, Capparelli EV, Lallemant M, Urien S. Antiviral Therapy 2014, doi:10.3851/IMP2876.
Summary: Lopinavir/ritonavir (LPV/r) is available in a liquid formulation far from ideal for treatment of children in resource poor settings. Flexible, low-cost, solid, fixed-dose oral combinations (FDC) of LPV/r with nucleoside reverse transcriptase inhibitors (NRTI) (LPV/ABC/3TC and LPV/ZDV/3TC) are needed to improve both management and adherence of children. This study aimed to develop appropriate drug ratios and dosing for each of the FDCs, and defined a flexible and simple FDC containing 40 mg LPV, 10 mg RTV, 15 mg 3TC and 30 mg ABC or ZDV. According to the weight-bands defined by WHO, therapeutic doses for children weighing 4-6 kg, 6-10 kg, 10-14 kg, 14-20 kg, 20-25 kg would be 2, 3, 4, 5, or 6 individual units administered by oral route twice-daily.